BioSpace News Archive

Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase II clinical trial of YH003 (anti-CD40 monoclonal antibody, mAb) (No. YH003004) in Australia.

TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company.

Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock.

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo culture system (IVC), INVOcell®, announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021.

Exicure, Inc.® announced the results of its previously disclosed independent internal investigation and a number of strategic actions aimed to reduce cash spend and prioritize the Company’s therapeutic pipeline.

Increasing prevalence of chronic diseases and growing awareness about regular body profiling are key factors expected to drive market growth.

Increasing government funding for vaccine production and growing emphasis on immunization are major factors expected to drive the market.

According to Emergen Research, the global clinical trial software market size was USD 900.3 Million in 2020 and is expected to reach USD 2,862.0 Million in 2028 and register a revenue CAGR of 15.6% during the forecast period, 2021-2028.

According to Emergen Research, the global endometrial ablation devices market size was USD 1,049.9 million in 2020 and is expected to reach USD 1,596.9 million in 2028 and register a revenue CAGR of 5.3% during the forecast period, 2021-2028.

Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation products, today announced the closing of its initial public offering of 4,166,666 shares of common stock and accompanying warrants to purchase 4,166,666 shares of common stock.